<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745678</url>
  </required_header>
  <id_info>
    <org_study_id>IRB- 34970</org_study_id>
    <nct_id>NCT02745678</nct_id>
  </id_info>
  <brief_title>Localized Therapeutics for the Treatment of Gastrointestinal Disorders II</brief_title>
  <official_title>Localized Therapeutics for the Treatment of Gastrointestinal Disorders II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate a novel thermosensitive topical gel formulation
      for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and efficacy of a new formulation in patients with mild-to-moderately-active Ulcerative Colitis using the Mayo Disease Activity Index (MMDAI)</measure>
    <time_frame>Between 4-6 weeks post-administration</time_frame>
    <description>Using Modified Mayo Score</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Thermosensitive gel formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thermosensitive gel rectal formulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thermosensitive gel rectal formulation</intervention_name>
    <arm_group_label>Thermosensitive gel formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntarily sign written informed consent.

          -  Male or non-pregnant and non-lactating females at least 8 years of age.

          -  Confirmed diagnosis of active, mild to moderate ulcerative proctitis or
             proctosigmoiditis extending no further than 40cm from the anal verge. Typically,
             baseline Mayo Disease Activity Index (MMDAI) score between 5 and 10 (indicating mild
             to moderate disease).

        Exclusion Criteria:

          -  Known infection with Clostridium difficile (C. difficile) and/or other enteric
             pathogens

          -  5-aminosalicylic acid (5-ASA) intolerance

          -  Current or recent (3 weeks) oral or rectal steroids

          -  History of thiopurine or Anti-tumor necrosis factor (Anti-TNF) alpha treatment for
             colitis

          -  Abnormal creatinine

          -  Previous small bowel or colonic resection,

          -  Anal sphincter incompetence,

          -  Current smokers.

          -  History or current diagnosis of Crohn's disease or indeterminate colitis.

          -  History of diverticulitis, collagenous colitis, celiac disease, recurrent pancreatic
             or known gallbladder disease.

          -  Unstable significant cardiovascular, endocrine, neurologic or pulmonary disease.

          -  Hemoglobin levels &lt; 7.5 g/dL.

          -  History of sclerosing cholangitis, cirrhosis, or hepatic impairment

          -  Pregnant or at risk of pregnancy.

          -  Some medications to treat UC are prohibited during participation in the study,
             including laxatives and anti-diarrhea medications; oral 5-ASA agents and daily fiber
             supplements are allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>August 14, 2018</last_update_submitted>
  <last_update_submitted_qc>August 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sidhartha R Sinha</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Enema</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

